Rare Disease New Drug Turns Profit, But Executives Sell Shares

Liquidia Corp. (NASDAQ: LQDA) announced that following the successful U.S. launch of Yutrepia®, its inhaled therapy for pulmonary arterial hypertension (PAH), it expects full-year 2025 net product sales of $148.3 million, or roughly KRW 190 billion, driven by two consecutive profitable quarters in the second half. On an annual basis, the company recorded a net loss of approximately $68.9 million (about KRW 90 billion), reflecting higher selling, general and administrative expenses as well as increased royalty and interest charges. However, Liquidia ended 2025 with cash and cash equivalents totaling $190.7 million (approximately KRW 250 billion), providing sufficient runway for ongoing commercialization and upcoming clinical programs.

Looking ahead, the company plans to broaden the pool of physicians prescribing Yutrepia, expand its commercial team and advance its next-generation inhaled treprostinil candidate, L606, into late-stage clinical trials. Liquidia also noted that its ongoing patent litigation with competitor United Therapeutics remains a critical variable in sustaining long-term commercialization of Yutrepia.

In insider trading activity, Chief Medical Officer Dr. Rajiv Sagar sold approximately $1.3 million worth of common stock on March 13, followed by a reported sale of around $2.5 million in shares by venture capital investor Cannon VIII between March 26 and 27, marking a series of recent insider divestitures.

On March 5, Liquidia’s management presented its 2025 financial results and business update, touting Yutrepia as “one of the premier prescription drug launches of the past five years.” Despite this positive framing, shares experienced a short-term pullback as investors weighed the company’s path to sustained profitability.

Finally, late February saw United Therapeutics introduce TreSMI™, a new treprostinil inhalation therapy designed to reduce coughing, while the outcome of the pivotal ‘327 patent case remains pending. In parallel, several brokerages have recently raised their price targets on LQDA shares. As a developer and marketer of inhaled treprostinil therapies for rare cardiopulmonary diseases such as PAH and interstitial lung disease-associated pulmonary hypertension, Liquidia continues a long-running patent dispute with United Therapeutics. The U.S. rare disease treatment market remains robust, supported by premium pricing and broad insurance coverage, but is characterized by significant volatility driven by patent litigation and competition within narrow therapeutic classes.